![3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation - ScienceDirect 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S193687982101339X-fx1.jpg)
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation - ScienceDirect
![Davide Capodanno on X: "My editorial to the EVOLVE Short DAPT study, from @ajaykirtane and colleagues (congratulations!). Interesting result and insightful data in a rapidly changing scenario that has more to say. Davide Capodanno on X: "My editorial to the EVOLVE Short DAPT study, from @ajaykirtane and colleagues (congratulations!). Interesting result and insightful data in a rapidly changing scenario that has more to say.](https://pbs.twimg.com/media/EvfZO08XIAEDhV4.jpg)
Davide Capodanno on X: "My editorial to the EVOLVE Short DAPT study, from @ajaykirtane and colleagues (congratulations!). Interesting result and insightful data in a rapidly changing scenario that has more to say.
![Three-month DAPT after PCI with Synergy stent supported in EVOLVE Short DAPT trial - Cardiovascular News Three-month DAPT after PCI with Synergy stent supported in EVOLVE Short DAPT trial - Cardiovascular News](https://cardiovascularnews.com/wp-content/uploads/sites/14/2020/06/Ajay-Kirtane-WEB-300x201.jpg)
Three-month DAPT after PCI with Synergy stent supported in EVOLVE Short DAPT trial - Cardiovascular News
![EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com](https://d14d5nk8lue86f.cloudfront.net/s3fs-public/2018-09/D1C8427E-8A1B-4977-85E5-49898050DEE7.png)
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
![SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal](https://www.jacc.org/cms/asset/08a80e15-6f4a-4e9c-8d8b-c47c239e64d8/s0735-1097(20)31861-1.fp.png)